Part III — Full Reading Version: Other Materials

Part III: Other Materials

01What Part III Is — A Home for "Neither" Materials

The creation guide splits into three parts. Part I covers product information summaries; Part II covers advertisements placed in professional print journals. So how are materials that fit neither category governed? The answer is Part III, titled, fittingly, "Other Materials." Slides an MR uses to explain a product, proceedings of lectures and study meetings, posters and panels at academic venues, notices to medical institutions, disease-explanation pamphlets, patient medication-guidance leaflets, product lists, compatibility tables, congress abstract collections, journal reprints, literature digests — most of the paper and digital handed out in daily practice actually belongs here.

Part III is built from eleven chapters. The chapter breakdown is fine-grained by medium and use because materials with different characters demand different points of vigilance. A leaflet handed to a patient and an abstract collection released only on request to a medical professional invite entirely different kinds of deviation. So rather than throwing out one blanket principle and stopping there, the guide works out the specifics chapter by chapter.

02How to Judge an Unspecified Material — The Foreword's Spirit Becomes the Operating Rule

Part III's defining feature is that it assumes, from the start, that "materials with no explicit provision here" will inevitably appear. Media evolve; new ways of presenting information arise one after another. The guide cannot list them all in advance. So is a material with no explicit rule free? No.

When there is no explicit provision, judge by returning to the intent of the product information summary and to the JPMA Code — this is Part III's operating rule. It translates into practice the very spirit of the foreword. The foreword made clear that the guide states basic matters and is not exhaustive, and that matters outside its provisions remain subject to the Pharmaceuticals and Medical Devices Act, the Standards for Fair Advertising, the guidelines for sales information provision activities, and the JPMA Code. Part III lowers that thinking one rung and forecloses the notion that "not in the manual = no answer = anything goes."

Why Send the Reader Back to "Intent"

A mindset of matching clauses one by one freezes the moment a situation has no matching clause. To keep thought from freezing there, the guide sets the purpose behind each prohibition — deliver accurate information to medical professionals, avoid creating misunderstanding, advance proper use — as the final point of reference for judgment. By showing a destination rather than a procedure, it stays able to handle unknown media.

03Three Threads Running Through Part III

The eleven chapters look scattered, but three shared disciplines bind them. Whichever chapter you read, noticing which of these threads it touches makes the whole easier to grasp.

Thread One: Materials Provided "On Request" Are Not Pushed

Congress presentation abstracts and proceedings, journal reprints, literature digests — these are provided only when a medical professional asks for them. They are not something a company hands out proactively. Why honor passivity this much? Such materials can contain presentation data whose medical evaluation is not yet settled, or a body of literature shaped by one company's selection. If a company forces them on someone who never asked, that turns from information provision into promotion.

So the brakes are placed not in "good intentions" but in numbers and structure: a ceiling on the number of copies, a ceiling on the distribution period, and, for Web posting, keeping the material independent of the product page, limiting access to the individual who requested it, refusing a setup where anyone can view it with a single Yes/No click, and not actively steering people to it by email. Passivity is secured operationally.

Thread Two: For Patients and the General Public, Disease Explanation Is the Rule

Disease-explanation materials and patient-facing materials reach the eyes of patients and the general public. Two dangers loom largest here. One is steering toward a specific drug; the other is leaving the impression of a confirmed diagnosis — "with these symptoms, I must have this disease."

So the rule is to stay with explaining the disease: name a drug only down to its therapeutic-class name, and present coping options fairly without tilting toward a particular drug. Self-check tools, too, must avoid the impression that symptoms alone settle a diagnosis, and should prompt consultation with a physician. Risk explanations, even when medically correct, are arranged so as not to breed the misunderstanding that one "will surely develop" or "will surely be cured." Lay readers read neither the package insert nor the review report. Precisely for that reason, the care of not letting a single presentation choice form a false picture weighs even more heavily here than in materials for professionals.

Thread Three: Lists and Comparisons Forbid Deliberate Omission

Materials that line up several products — product lists, compatibility tables — by their structure carve out a slice of the information, and so easily breed bias or a distorted picture of the whole. Quietly dropping an inconvenient product, blurring the selection criteria — such deliberate omission is the gravest risk.

So the guide requires either taking up all related drugs or taking up a product group selected by a clear standard, and it forbids any presentation that emphasizes a particular product or disparages competitors. Because the very act of lining things up carries the weight of comparison, what is included and what is left out must be fair.

04A Map of the Eleven Chapters

Each chapter of Part III is arranged by medium and use. Here only the overall picture is shown; the details unfold on each chapter's page.

• Chapter 1 Presentation Content: visual aids and tablet digital materials an MR uses to explain a product. Balanced against safety rather than tilted toward efficacy.
• Chapter 2 Lecture and Study-Meeting Proceedings: records of meetings the company hosted or co-hosted. Brakes on handling unpublished data.
• Chapter 3 Congress Posters and Display Panels: items posted at a display booth, made under the intent of whichever chapter the content suits.
• Chapter 4 Notices: announcements of approval, price listing, packaging change, and the like. If concrete results are carried, treat as a specific-item product information summary.
• Chapter 5 Disease-Explanation Materials: governed separately for patient-facing and professional-facing versions.
• Chapter 6 Patient-Facing Materials: medication-guidance materials, and patient-explanation materials used by medical professionals.
• Chapter 7 Product Lists: the chapter where the ban on deliberate omission comes to the fore.
• Chapter 8 Compatibility Tables: results state only the facts of physical-chemical change, with no evaluative wording.
• Chapter 9 Congress Abstracts and Proceedings: provided on request, with fine brakes on copy counts, periods, and fairness of selection.
• Chapter 10 Journal Reprints: extracted at an appropriate unit of cut, provided on request.
• Chapter 11 Literature Digests: built from abstracts of peer-reviewed original papers, with the selection standard stated.

05Part III Seen Through the Discipline of Science

Part III's materials span many media, but the honesty demanded of the information is continuous with Parts I and II. The hierarchy of evidence (meta-analysis and systematic review > randomized controlled trial > observational study > case report > expert opinion) remains the measuring stick here too. Congress abstracts and proceedings in particular mix in data that has not been peer-reviewed and whose evaluation is not yet settled. Hence the frame of passivity — "on request" — and of authorship under the company's own responsibility.

The design philosophy of sealing off "true but misleading" is tested most of all in Part III. A compatibility table states only the facts of physical-chemical change and avoids the evaluative word "compatible"; a product list may carry the unit drug price but not the daily drug cost or the patient's out-of-pocket share — both because the guide knows that a single choice of which facts to select and how to present them can breed a false impression. The asymmetric duty to disclose safety even when unfavorable takes concrete form in presentation materials as the rule to make safety stand out at least as prominently as efficacy.

→ Source page: Part III: Other Materials

Chapter 1: Presentation Content

Presentation content refers to material that a medical representative shows in hand while explaining a product to healthcare professionals. It covers not only printed visual aids but also digital material run on a tablet. In front of every page or screen there is always a person doing the talking, and spoken commentary is layered on top. That single fact sets this material apart from every other kind. For that reason the Creation Guide states at the outset that the intent of Chapters 1, 2, and 3 carries over directly into this format.

01Why "material with a presenter" gets its own chapter

The foreword is the constitution of the whole Guide. It states plainly that the basis of proper-use information is the package insert, and that product information summaries and the like sit in a "supplementary" position to it. The word "supplementary" is not light. What supplements cannot exceed what it supplements. Against the original — the approved content — material may not step one character beyond the approved scope. Presentation content is no exception.

So why a separate chapter? The reason lies in the nature of the medium. Slides are turned one at a time, the presenter's words layer over them, and the listener forms an impression on the flow of the moment. Material that remains as continuous text can be reread and surveyed as a whole, but presentation content is dominated by "the one page on screen now." Through the combination of order, emphasis, and spoken commentary, a written fact can stay factual yet still create a mistaken impression. The foreword's other implication — that the duty not to lie and the duty not to mislead are two different things — is tested most sharply here.

02Guaranteeing the efficacy–safety balance through structure

Efficacy lined up everywhere, safety reduced to a footnote — this is the bias most likely to arise in presentation material. The Guide does not leave it to the writer's conscience; it binds it through structure. It requires that efficacy and safety be balanced across the content as a whole, and that safety (results) be set out as an independent item, made at least as prominent as efficacy (results).

The asymmetry of "at least as prominent" is the point. It is an expression of the foreword's duty to disclose safety even when it is unfavorable to one's own product. Efficacy invites being told; safety invites being held back — and to cancel that natural slope, weight is deliberately placed on the safety side. Specifying matters down to the level of appearance — font size, item independence, placement — turns "accurate and not misleading" into an operable rule.

Do not over-emphasize through visual effects

Truncating a graph axis, playing up a difference with arrows, making only one part stand out with color or bold — such staging manipulates impression without changing a single figure. Because presentation content can even use animation and screen transitions, the room for exaggeration is wider than on paper. Hence the explicit brake: "do not over-emphasize through visual effects." Think of it as Chapter 1's foundational discipline — "no convenient extraction, no emphasis by color or bold" — read across to the medium of the screen.

03If you state a feature, keep the basis inside the same content

If a product's features are described, the supporting data must be shown within the same content. Saying "it is superior" out loud while leaving the basis in a separate document makes verification impossible. If clinical results are included, the design of that trial — subjects, methods, the positioning of endpoints, and so on — must be stated alongside. The source is to be noted on each page (each slide): the state of affairs must always allow tracing "where the number on this one page came from."

This connects directly to one of the foreword's three pillars — guaranteeing verifiability through structure. Material may not remain in hand once the explanation is over. Precisely for that reason each single page must carry its own source. Where the company is involved in a trial, the conflict of interest (COI) is recorded in the trial-design section or the like. Not hiding who funded a trial is part of honesty.

Why stating the trial design is mandatory

Even the same "statistically significant" carries entirely different weight depending on whether it is the result of a pre-specified primary endpoint in a double-blind confirmatory trial, or a nominal p-value pulled from a post-hoc subgroup. The former supports a conclusion; the latter is only the entrance to a hypothesis. A slide that omits the design strips this distinction from the listener. So stating the design is not decoration but the premise for reading the number correctly.

04Quarantining reference information — never at the center

Reference information means results obtained secondarily within the approved scope, or findings whose relation to efficacy is not necessarily clear. It can be useful, but it differs in character from the principal basis of approval. Make it the lead and the listener mistakes it for the approved efficacy itself. So the Guide fences reference information tightly even in presentation content.

• Keep reference information to one-quarter or less of the whole content. Preserve the hierarchy by volume.
• On each page that carries reference information, state clearly that it is reference information.
• Do not open with reference information. Do not make a piece centered on reference information.
• Do not attach a supervisor's comment to reference information — so that information treated as reference is not elevated by a third party's authority.

The one-quarter ceiling is aligned with the treatment of reference information in Part I, Chapter 3 (item-specific product information summary). The idea running through the whole Guide — protecting the hierarchy through volume and placement — stays consistent even when the medium changes.

Make the DI easy to consult

Presentation content is a place to show summarized information, not a place to cover the full caution information. So a path that reaches the product information (DI) quickly — on a tablet, a link or a jump to the relevant page — must be prepared. Being able to return to the package insert, the original of approval, at any time: that is the minimum condition for implementing the "supplementary" position.

05What must not be made in this format

The Guide defines what must not be made in this format just as firmly as what may be made. Conference-abstract collections and literature-abstract collections must not be made in the form of presentation content.

The reason lies in the origin of the material. Conference-abstract and literature-abstract collections are by nature passive material provided "in response to a request" from healthcare professionals, and pushing them onto people is to be avoided (this is set out in detail in the later chapters of Part III). Dress them up as presentation material that a representative actively explains on rounds, and the passive character collapses; the premise of "responding to a request" is hollowed out. Borrowing the look of a medium to swap its character — this falls into the same pit as the notion the foreword shut down: "if it isn't in the manual, it's free." So it is prohibited at the entrance.

→ Source page: Chapter 1: Presentation Content

Chapter 2: Lecture and Study Meeting Records

A proceedings collection from a lecture or research meeting takes something genuinely valuable—the discussion among clinicians and the sharing of clinical experience—and reassembles it on the printed page. Materials built from round-table discussions or interviews are similar: an expert's living words help the reader understand. That very strength carries a hazard. A remark made in the room is spoken with the context and the caveats of that moment, yet the instant it is cut out and fixed into a printed record, the context falls away and the fragment can walk off on its own. This chapter makes the most sense when read as an answer to that risk of fragmentation.

01What this covers, and the single standard that runs through it

The subject here is materials that gather the records of lectures or research meetings the company hosted or co-hosted. Transcribed round-tables and collected expert interviews belong to the same family. Whether the meeting was open or closed, and however it was run, does not matter. Rather than drawing a line by format, this chapter governs everything by one standard: the intent of the industry association's code of practice.

Why not distinguish by format? Allowing the thought that "a small closed meeting can be treated more loosely" opens a loophole. The object of discipline is not the meeting's outward form but the nature of the information that is finally printed and distributed—this chapter places that stance up front.

The weight of being a "record"

A reader takes a proceedings collection not as invention but as the record of a meeting that actually took place. To honor that trust, the content must be what was genuinely said at the meeting and must fall within proper bounds. The persuasive force of the record form raises the quality of information when used correctly, but misused, it lends an improper claim the false backing of "this really happened."

02How to write about efficacy and safety

For any part touching a product's efficacy and safety, apply directly the thinking set out in Chapters 1 and 2 of this commentary: stay within the approved scope, keep expression proportionate to the strength of the data, and do not cherry-pick the convenient parts. Being a proceedings collection does not loosen the standard.

When clinical results are included, place at their head a note to the effect that "for warnings, contraindications and the like, refer to the DI page." A layout in which efficacy meets the eye first and risk comes later tilts the reader's judgment toward the benefit side. Signaling where the risk information lives, right at the top, is a structural brake that puts favorable and unfavorable information on the same table.

Do not conflate statistical significance with clinical meaning

A frequent slip in recorded remarks is reading a statistically significant difference as clinical value in itself. A small p-value and a difference that matters to patients are separate questions. Even when transcribing a presenter's words, the editorial side bears the responsibility of checking that conclusions are not inflated beyond what the data show. A pre-specified primary endpoint result and a finding discovered after the fact carry different evidentiary weight—holding that distinction is what it means to follow the discipline of science.

03How to build the cover

The cover states the name of the meeting, the venue, and the date held. This is a statement of provenance that guarantees the collection is the record of a specific, real meeting. Only when it is clear when, where, and at what meeting the words were spoken can the reader place the content in context.

The product logo, by contrast, is not placed on the cover. The protagonist of a proceedings collection is the discussion exchanged at the meeting, not product promotion. A logo dancing on the cover creates a gap between the pretense of an academic record and the reality of sales promotion. The aim is to avoid miscasting the material's character at the very first page.

Handling unpublished data

Conference-presentation data, the company's own case experience, and other results not yet published as papers are, as a rule, not included. The exception is results evaluated at the time of approval. Approval-time evaluation results have passed regulatory review and rest on a confirmed foundation of reliability. Putting numbers that have not been through peer review or formal publication into a collection would prop up the weakest-footed information in the evidence hierarchy with the authority of print. So the line is drawn clearly.

04The duty to include the DI (product information)

If the collection contains content about the company product's efficacy or safety, include the corresponding DI (product information) alongside it. Once an expert's remark touches on effect or use, the official information needed to interpret it correctly must be handed to the reader within the same material. A state in which only the remark survives, unaccompanied by the approval information that grounds it, inverts the complementary relationship—a configuration to avoid.

05Presenter comments and the ban on impression-based expression

The heart of a proceedings collection is the experts' comments. Yet even a presenter's words do not escape compliance with the code of practice. The page must never ride on the speaker's authority to carry a claim beyond the approved scope.

Same data, different impression

Even with identical clinical results, a single turn of phrase from the speaker can change the impression left on the reader. "Efficacy was suggested" and "efficacy was proven" reach different destinations even when the data are the same. Editing a collection requires examining, word by word, whether the speaker's expression is balanced against the certainty of the data. The more impassioned the comment, the more carefully this check is done.

A quantitative brake on reference information

Reference information is not only kept off the cover; in the body it must not exceed one quarter of the total content. Setting a clear ceiling on quantity prevents reference material from encroaching on the main subject. The foreword's stance is to govern by the intent of higher norms even where no explicit numeric standard exists—but here a concrete yardstick, "1/4," is given. Once the boundary is expressed as a number, observing it becomes the minimum line.

→ Source page: Chapter 2: Lecture and Study Meeting Records

Chapter 3: Conference Posters and Exhibition Panels

A booth on the conference floor. Panels on the wall, posters on the table, a single board that makes a passing physician stop. Part III, Chapter 3 covers exactly this: posters and exhibition panels shown at academic conference venues. The text itself is brief. But brevity does not mean the rules are loose. Folded into that brevity is an assignment — the writer must apply the spirit of the whole creation guide and judge for themselves.

01Why "according to the content"

An exhibition panel is a medium with no fixed shape. Some merely display the product name in large type, like a name-only advertisement. Others line up clinical-trial figures and argue the product's features, like a product information summary. Some confine themselves to explaining a disease. Handing down a single self-contained article "for posters and panels" would simply fail to fit. The discipline is decided not by the name of the medium but by what is written on it — that is the meaning of "build it according to the spirit of the applicable chapter."

This is a plain extension of the foreword's spirit. The foreword states that the guide sets out basic matters rather than covering everything, and that areas left unwritten still fall under the Pharmaceuticals and Medical Devices Act, the Fair Advertising Standards, the sales-information-provision activity guideline, and the JPMA Code. The fact that the manual does not spell out "make posters like this" line by line does not mean freedom. The opposite: the writer must work out what their panel effectively amounts to, and shoulder the constraints of the nearest chapter themselves.

Reading the panel's content for what it is

The clue for judgment is what kind of material the display is. If it carries concrete results, features, and data to speak about one's own product, the spirit of the product information summary — especially the specific-item version — applies. Never exceed the approved scope by a single character; if you write efficacy, show safety at equal or greater prominence; show sources and trial design. Every item of Chapter 1's basic considerations, the foundation, comes down onto the panel intact.

02Reference information — the front line against "true but misleading"

For the handling of reference information, this chapter defers entirely to Part I, Chapter 3, section 2-(8) of the specific-item product information summary. Reference information means secondary material such as results within the approved indication, or the pharmacological action that underpins it. The trouble is that such information "is factual, yet depending on placement can look like the core of the approval."

So the specific-item rules require that reference information not be placed on the cover or the pages immediately following it, not exceed one quarter of the printed area excluding the cover and the DI, and carry no supervisor's commentary. Applying this to an exhibition panel means reference information must not sit where a visitor's eye lands first, nor occupy the largest share of the surface.

The quantitative fence of one quarter

The ceiling "reference information up to one quarter of the surface" is a quantitative fence, not a qualitative prohibition. Why bind it by quantity? If information that is not the core of approval fills half the surface, the weighting a visitor takes away is distorted even if every spot is annotated "reference information." Area sends a silent message. The quantitative cap is the brake that keeps that silent message from stepping past the approved scope.

03Making the DI easy to consult inside the booth

The other explicit requirement is to keep the package insert readily consultable inside the booth. This implements the foreword's positioning: product information summaries and the like complement the package insert, and the original authority is the approved content. The panel is not the original. It is only a window onto approved information. So when a visitor wants to check "what exactly are the contraindications, warnings, and dosage," the original must be within immediate reach.

The same requirement recurs for presentation content and lecture-record collections. The medium changes, but the principle does not: the material sits below the package insert and must never cut off the route back to the original. Whether by tablet or by a printed package insert, the right approach is to provide a path that lets the visitor consult it without leaving the booth.

04The restraint the exhibition setting demands

A conference booth is a place where many visitors pass through in a short time. A momentary visual impression carries weight. For that very reason, overemphasis through visual effects, or a layout that pushes safety aside and enlarges efficacy alone, works especially well here — and is especially dangerous. Because the text is short, the writer bears the responsibility of applying Chapter 1's spirit with their own hands: the balance of efficacy and safety, the ban on exaggeration and misleading, scientific grounding with fairness and objectivity.

The related thinking is continuous with the Fair Advertising Standards (guide to the Fair Advertising Standards) and the JPMA Code (guide to the JPMA Code). The thinner the wording in a given area, the more one needs the posture of returning to these higher norms to judge.

→ Source page: Chapter 3: Conference Posters and Exhibition Panels

Chapter 4: Notification Documents for Healthcare Institutions

A new drug has finally been approved. A launch date is set. A new dosage form is added. The package size changes. The product appears on the NHI price list. Every time a product reaches the market, there is a moment when a company wants to let medical institutions and healthcare professionals know. The single sheet handed out at that moment is what this chapter calls a notice document. It looks light, almost like an administrative memo. Yet the Guide sees a trap hidden in that lightness. The label "notice" can become a side door through which efficacy and safety claims — which would otherwise be tightly governed — slip in dressed up as a mere announcement.

01What a notice document is

A notice document announces milestones concerning one's own prescription drug to medical institutions and healthcare professionals. The events it typically covers include:

• obtaining a new approval
• announcing a new launch (start of sales)
• an additional approval for indications or dosage and administration
• listing on the NHI drug price standard
• addition of a dosage form
• a change in package unit

Its audience is the medical institution, not the general public. This is the decisive difference from disease-explanation materials and patient-facing materials. Assuming readers who are specialists in prescribing and dispensing, it conveys the necessary milestone concisely. That is its proper role.

Press releases are not included

Even though it is also a kind of "announcement," a press release aimed at the media, investors, or society at large is not part of the notice document covered by this chapter. The two differ in both recipient and purpose. A press release is a disclosure of corporate activity; it is not a material that directs medical institutions in how to use a particular drug. Treating the text of a press release as something to be transplanted directly into a notice for medical institutions mistakes the reach of this chapter.

02Why an "announcement" still needs brakes

The foreword positions materials such as product information summaries as a complement to the electronic package insert. The original text is the approved content, and a material cannot exceed that approved scope by a single character. The notice document, too, lives under this constitution. Notifying the fact that "it has been approved" is itself within the approved scope, so little goes wrong. But the instant you step further into "approved, and this is how well it works," it becomes an efficacy claim and enters the far heavier territory of approved scope, supporting data, and balance with safety.

The duty to "not mislead, and to convey accurately" is at work as well. Not writing falsehoods and not letting a false image form are separate duties. If a launch announcement carries a figure that evokes efficacy, or a line that suggests superiority over a competitor, then even with no lie anywhere in the text, the reader forms the image "this drug works especially well." The Guide is wary of the notice document becoming the entrance to that kind of impression-shaping.

03Carry concrete results, and it stops being a notice

This is the heart of the chapter. If you wish to place concrete results on a drug's efficacy or safety into a notice document, it is no longer a mere announcement. It must be prepared as a specific-item product information summary. The title may remain "notice," but the moment the content begins to speak of clinical data, the governing discipline switches over entirely.

Why is this switch required? Showing concrete results means handing over information that directly affects the reader's prescribing decision. That brings with it the whole verifiability framework a product information summary carries: the quality of the evidence (a confirmatory analysis, or an exploratory post hoc or subgroup result), the symmetric disclosure of efficacy and safety, the clear citation of sources, and the date of preparation or revision that preserves the version. The announcement format does not exempt any of these. This rule blocks the escape into light treatment under the banner of "just a notice."

Where is the boundary

The test is simple. Does the statement become material that lets the reader "evaluate" the drug's efficacy or safety? "Launching on the Xth" stays a notification of fact. "Met its primary endpoint in trial XX and is now launching" shows the achievement as a result and steers toward an impression of superiority. The latter is no longer an announcement. When in doubt, ask whether the document still stands as a "notice" with that sentence removed. If it cannot be removed, it is not an announcement but a claim.

04Do not import advertising catchphrases or the "features" section

There is another clear prohibition. Catchphrases used in journal advertisements, and the wording of the features section of a comprehensive product information summary, must not be diverted into a notice document.

This prohibition has its reasons. An advertising catchphrase is promotional language honed to catch attention within limited space. The features section is the very place the Guide itself names as "most prone to exaggeration," and where it strictly imposes the balance of efficacy and safety and the attachment of supporting data. Carry such strongly promotional expressions into a thinly-regulated notice document, and the promotion walks off on its own — without the brakes that should accompany it (citation of the basis, symmetry with safety, the page reference). The result is, in substance, an advertisement borrowing the guise of an announcement.

05What this chapter embodies

The rules for the notice document are short. But within that brevity is concentrated the whole design philosophy of the Guide. A material's character is decided by its content, not by the name on its cover. Title it "notice" all you like — once it begins to speak of concrete efficacy and safety results, it is a specific-item product information summary and owes the corresponding discipline. The Guide closes, one by one, the routes by which lightening the label lets one escape the rules.

Here is the most practical expression of the foreword's principle that "what is outside the rules is not free." Even on a plain single sheet called a notice document, the higher norms run through: the principle of complementarity, the prohibition on misleading, and the securing of verifiability.

→ Source page: Chapter 4: Notification Documents for Healthcare Institutions

Chapter 5: Disease Explanation Materials

01What a Disease-Education Material Is

A disease-education material explains an illness: what symptoms appear, what mechanism drives it, and how to live with it. On its face it is not a product advertisement but an aid to understanding the disease itself. In practice, though, because a pharmaceutical company produces it, the company's own product always sits somewhere behind the page. That is precisely why the creation guide treats this material as its own chapter and holds it to rules distinct from ordinary promotional pieces.

The starting point is classification. Even within "disease education," the permitted range of expression changes completely depending on who receives the material and why. The guide divides it, by audience and purpose, into patient-facing disease-education materials and healthcare-professional-facing disease-education materials. Whether the reader is an ordinary patient or a specialist who holds prescribing authority is the premise on which every later judgment rests.

02The Frame Patient-Facing Materials Must Hold

Patient-facing materials sit under the Pharmaceuticals and Medical Devices Act, the fair advertising standards, and related rules. The content must be necessary and appropriate for a lay reader, that is, a patient without medical training. This premise of a lay reader imposes tight constraints, because errors a specialist would correct from context may be taken at face value by a patient.

At the core lies one line that must not be crossed: the material must not be read as the advertisement of a specific drug. If, under the guise of disease education, it effectively steers patients toward the company's own product, it is nothing more than evasive promotion slipping past the ban on advertising prescription drugs to patients. The guide builds up concrete sub-rules to keep this line intact.

Keep the Explanation of the Disease at the Center

A patient-facing material is built around explaining the illness. Even when it touches on treatment, it should present the commonly assumed options fairly and not lean toward any specific drug. Drawing one option large and the others small lets the layout itself argue "choose this drug." Fair presentation means neutrality reaching down to layout, length, and tone.

No Clinical Results; Stop at the Therapeutic-Class Name

Patient-facing materials carry no clinical results for treatment drugs. Response rates and figures are information whose interpretation requires specialist premises, and a patient cannot weight them correctly alone. When a drug must be mentioned, the material stops at the therapeutic-class name. By withholding the specific product name, it physically preserves the boundary between "explaining the disease" and "recommending a product."

Leave a Bridge to Seeing a Doctor

Patient-facing materials prompt consultation with a physician where appropriate. Rather than letting the material stand alone, leaving room to connect to a specialist's judgment bears directly on patient safety. When a self-check or similar self-assessment tool is included, it must not give the impression that the presence or absence of symptoms settles the diagnosis. A check is only a trigger; confirming a diagnosis is the physician's role, and the material itself must state this line.

The Discipline of Avoiding Misunderstanding

An explanation of risk, even if medically correct, can depending on its wording invite the misreading that "if it applies to you, you will certainly develop the disease." Care is needed so that probabilities and risk factors are not reread as deterministic certainties. The opposite misreading is equally forbidden: do not give the impression that one will certainly be cured. Speaking of hope is not the same as promising a cure. Nor should symptoms alone be made to seem to settle the disease. Each of these gives concrete patient-facing form to the foreword's spirit of avoiding not only falsehood but also misunderstanding.

Naming the Company

Patient-facing materials state the name of the company that produced them. Making clear who issued the information is a premise for the reader to gauge the nature of that information. Disease education that hides its source is itself wanting in honesty.

03The Different Discipline for Professional-Facing Materials

When the reader is a healthcare professional, the range of information that may be carried widens. But this does not mean "anything goes"; it is a conditional widening, on the terms that if you carry it, you must follow the matching framework.

If concrete clinical results are to be included, the material is prepared as a specific-item product information summary. The product information summary is a fixed vessel for presenting evidence without excess or deficiency and without steering; once results are spoken of, they are made to obey its discipline. Even when stopping at the therapeutic-class name, if reference information is added, it is arranged in the spirit of a specific-item summary. And as with patient-facing materials, the company name is stated.

04Why Divide So Finely

Each sub-rule looks fussy, yet the root is single. Treat the electronic package insert as the original, complement it, and avoid both falsehood and misunderstanding. The provisions of this chapter are that foreword spirit made concrete according to differences in the reader.

A patient can hardly measure the weight of figures alone, and a slight tilt in wording moves decisions about care-seeking and medication. So strong information such as product names and clinical results is suppressed, while fairness of explanation and a bridge to consultation are preserved. A healthcare professional can interpret figures, but precisely because they can, the presentation is placed on the discipline of the product information summary to prevent arbitrary cropping. Even areas the Act does not address in explicit text are governed by higher norms such as the fair advertising standards and the code. The foreword's posture of filling unwritten ground with higher norms is alive here too.

→ Source page: Chapter 5: Disease Explanation Materials

Chapter 6: Patient-Directed Materials

This chapter deals with materials that reach patients rather than healthcare professionals. When the recipient changes, the rules change too. A specialist can return to the package insert or the review report and judge for themselves whether a piece of information holds up; a patient has no such footing. So in this domain the harder question is not what to include but what to leave out, and where to stop. Read against the spirit of the foreword, the duty to complement the electronic package insert as the original, and to avoid not only falsehood but the seed of misunderstanding, is tested most severely in the materials that sit closest to the patient.

01The line shifts with who receives the material

The axis that separates the two is simply this: who directly receives and reads the material. Medication-guidance materials are built on the premise that the patient reads them. Patient-explanation materials are kept by a healthcare professional and shown to the patient as an aid to dialogue. The former aims for "the patient does not err even when alone"; the latter aims to "accurately support the professional's explanation." Because the aims differ, so does the depth of information that may be entered and the kind of clinical data that may be attached.

Two premises are shared. Both must comply with the Pharmaceuticals and Medical Devices Act and related laws, and both must state the company name. Health information whose source is hidden loses credibility by that fact alone. Showing who issued the material, and bears responsibility for it, is the minimum line of patient protection.

02Medication-guidance materials — confined to what is needed for safe use

Medication-guidance materials are made for patients who are actually using a particular drug, to help them keep using it appropriately. At the center sits the information needed for safe use: how to take the medicine, precautions for use, cautions about adverse reactions, how to store it, and the like, the practical information that lets a patient avoid danger and not get lost in daily dosing.

Stop effect claims at "the minimum"

Effect is described only at the necessary minimum, or through a figure conveying an image of the effect. Concrete clinical data, numbers and trial results, are not included. This is not to withhold information but to prevent patients from judging their own condition and adjusting their dosing on their own. A figure like "effective in X%" carries context for a specialist, but for a patient it easily invites the mistaken expectation "it should work just as well for me," or the opposite self-judgment "if it isn't working, I'll stop." A statistically significant difference is not the same as clinical significance, and an average effect does not transfer directly to any one patient. That gap must not be left for a single patient to fill.

Referring to other companies' products; stating the intended recipient

Only where reference to another company's product is genuinely necessary, as for co-administration cautions, it is made in principle by the generic name. Bringing in a brand name risks turning the mention into commentary on a competitor dressed as comparison. Narrow the scope by necessity, keep the wording to the generic name — this two-step guard separates the provision of safety information from criticism of others.

Further, to keep the intended recipient from being mistaken, the material states plainly "To those taking (using) ___." Putting on the face of the material that it is for people already using the drug cuts off any reuse as de facto solicitation of those not yet using it. This too is a concrete form of the foreword's spirit of avoiding misunderstanding.

03Patient-explanation materials — supporting the professional's explanation

Patient-explanation materials are used when a healthcare professional explains things to a patient. They may therefore carry, as needed, content that goes further than medication-guidance materials: explanation of the disease state, coping methods, product information, how to take the medicine, adverse reactions, storage, and so on, within the range that helps understanding of the drug and the illness. Yet this depth is permitted precisely because a professional stands in between; it does not mean one may write freely.

Coping methods: fair and objective, within what is usually anticipated

When explaining the disease state and coping methods, write what is usually anticipated, fairly and objectively. Exaggerating one particular coping method, or drawing the picture of the disease in a way convenient to one's own product, becomes inducement wearing the face of explanation. The aim is that the patient understands their illness correctly, not that they are steered toward a product.

Clinical results — what may and may not be shown

When clinical results are handled, they are stated on a scientific basis, accurately, fairly, and objectively. Showing efficacy and safety in good balance is the crux. Lining up only the success stories while not touching adverse reactions or limits comes close to falsehood as a whole, even if every sentence is factual. Safety information is disclosed even when unfavorable to one's own product — this is the discipline of anyone handling evidence, and it cannot be conceded even in patient-facing materials.

04Do not step beyond the approved frame — restraint in indication and dosage

In patient-explanation materials, content outside the approved range of indication and dosage is not included. Beyond that, hinting at off-approval use under the guise of "reference information" is also avoided. Information of the form "not formally recognized, but it can also be used this way" may exist as material for a professional's judgment, yet handed out as a material it can promote off-label use. A material placed before a patient stays inside the public frame of approval. This is compliance with law and, at the same time, the foreword's stance of governing even unwritten territory by higher norms.

05State what must be stated, without fail

Common to both materials, the company name and a statement of the material's character are indispensable. For medication-guidance materials, "To those taking (using) ___"; for patient-explanation materials, "For healthcare professionals," shown on the face of it. Letting the material speak for whom and for what it exists — this small step keeps it from drifting into an unintended setting and breeding misunderstanding. The habit of making source and purpose explicit is the last fence for patient protection.

→ Source page: Chapter 6: Patient-Directed Materials

Chapter 7: Product Listings

A product list gathers several related drugs into a single table or chart so that healthcare professionals can tell them apart and choose among them more easily. It is a convenient tool, but a structurally risky one. Because it pulls only "part" of the information from multiple products (often including competitors' products) and lines them up, the way the extraction is done can distort the whole picture and make a particular product look superior — unintentionally, or by design. This is why one of Part III's three guiding lines, "no arbitrary omission in lists and comparisons," bears most heavily on this chapter.

01Why a List Demands Discipline — Connecting to the Spirit of the Foreword

The foreword places two duties on companies: the duty not to lie, and the duty not to mislead. These are distinct. A table can lead the reader to a false impression through the way its cells are combined, even when each cell is correct on its own. In other words, it can become a textbook stage for "true but misleading." That is why the prohibitions in this chapter concentrate not merely on forbidding falsehood, but on shutting down the steering effect of presentation.

A second point of connection is the positioning of product information summaries as a "complement" to the package insert. When a list deals with approved matters, it must transcribe the approved content exactly — not exceeding it by a single word, and not trimming it. Blurring the contours of an approval through summarization or symbols is a departure from the approved content, which is the original.

02The Permitted Forms of List — The Four That Are Allowed

You cannot build lists without limit. Creation is permitted only in the following forms, where both the purpose and the method are clear. Each is tied to the function of "aiding identification and selection," and each carries its own brake.

Indication / Dosage List — What "In Full" Means as a Condition

The heaviest constraint on this form is the rule that it is allowed only "when written accurately and in full." Indications and dosages carry meaning only once their limiting conditions and restricted wording are included. The pressure of making a list pushes toward extracting only the gist to save space. But a gist-only excerpt can make the scope of an indication look wider than it is, or erase the conditions on a dose. That is why, in this column, simplification itself is forbidden.

NHI Drug-Price List — Why "Only Up to Unit Price"

A price list is limited to the unit drug price (the price listed on the NHI price standard); you cannot calculate and post a daily drug cost or a patient's out-of-pocket cost. There are two reasons. First, daily drug cost varies greatly with assumptions about dosing and frequency, and depending on how those assumptions are set, it is easy to make your own product look cheaper. Second, out-of-pocket cost depends on insurance category and each patient's circumstances; presenting it in the format of a list creates the false impression of a uniform fact. By limiting the list to the unit price — an "immovable single point" — the rules prevent price comparison from becoming a tool of persuasion.

Generation-Classification List — A Classification Is a Claim

A generation classification such as "first generation / second generation" is convenient, but it is a framework that carries an evaluation. It tends to imply that later generations are superior. That is why this list may be made only when it is backed by external scientific grounds such as a guideline, and the grounds must always be stated alongside it. The act of showing the grounds is the very thought of the evidence hierarchy and verifiability — if you assert a classification, you must keep the reader able to check whose standard, and which one, you relied on.

03The Ban on Arbitrary Omission — How to Define the Population

The fairness of a list is decided not by what you put in, but by "what you left out." The Creation Guide requires fixing the range covered to one of two options: either listing "all" of the related drugs, or listing a group of products selected according to a "clear selection criterion." Dropping inconvenient products arbitrarily is not permitted.

If you set a selection criterion, the criterion must be shown in a form the reader can see, and every product meeting it must be picked up without omission. The requirement is that the criterion itself be neutral — such as "dosage forms including our own product" or "a specific drug class" — and that it not have been tuned after the fact to favor your own product. Shifting the criterion later to match an effect is the same fraud as a post-hoc analysis dressed up as a pre-specified one.

04The Ban on Emphasis — A List Arranges, It Does Not Argue

The role of a list is to aid identification and selection, not to assert superiority. Accordingly, any treatment that sets off the differences from competitors' products, or makes a particular product stand out, is forbidden. Drawing the eye to a particular row through manipulation of color, bold, frames, placement, or arrows also counts as emphasis. The same principle by which Chapter 1 warns against emphasis in figures and tables runs through the format of a list as well.

"Arranging" and "arguing" are different acts. A list is permitted only the former. Interpreting the meaning of differences, evaluating superiority, explaining the reason one should choose — these all overstep the bounds of a list, and lead straight to disparaging competitors or promoting oneself. If you want to discuss a comparison, that is not work the list format should take on.

05The List You Must Not Make — A List of Warnings and Contraindications

Safety information must be neither emphasized nor guaranteed, yet conveyed accurately without being trimmed — and this asymmetric treatment is fundamentally a poor fit for the excerpting format of a list. That is why this domain is excluded from being made into a list.

06Leaving a Version — Date of Preparation and Updating

A list should state its date of preparation and be updated as appropriate when its content becomes outdated. Approved matters, drug prices, and the grounds for generation classification all change over time. If an old list remains without being updated, it becomes a source of false information in itself. Stating the date of preparation reflects the same thought by which the sixteen items of Chapter 2 close with "date of preparation or revision" — making clear as of when the information stands, and keeping it in a state that can later be verified and recalled. It is unglamorous, but the foundation of trust lies here.

→ Source page: Chapter 7: Product Listings

Chapter 8: Compatibility Tables

01What a compatibility table is

A compatibility table compiles, as test results, what happens when a given product is mixed with other drugs, infusion fluids, or solvents. Picture the clinical setting where several injectables meet inside one infusion line. The table supplies the raw material a clinician needs to judge whether that combination produces turbidity, precipitation, or a drop in content—or whether nothing changes at all.

Getting its standing right is essential. A compatibility table does not hand the physician or pharmacist a verdict of "may mix" or "must not mix." It only presents the observed physical and chemical changes, together with the conditions under which they were seen. The final decision is left to the reader's expertise. That boundary connects to the design philosophy running through the whole Creation Guide.

02State the test conditions and the formulations examined

Compatibility results change when conditions change. For the very same two drugs, a difference in concentration, mixing ratio, temperature, light, observation time, or the diluent fluid can flip a clear solution into a cloudy one. That is why the conditions tested, and the specific formulations paired, must be stated.

Show only "no change" while hiding the conditions, and the reader will generalize a conclusion that does not fit the conditions on their own ward. This runs straight against the foreword's duty to avoid not only falsehood but also misunderstanding. The fact may be correct, yet a gap in how it is shown leaves a false impression—a textbook case.

Why recording conditions is a scientific discipline

Reproducibility is the foundation that supports the quality of evidence. When conditions are written down, the reader can check how far they overlap with their own administration plan. When they are missing, no such check is possible, and the result collapses into an unverifiable claim. The same spirit by which the Guide repeatedly demands citation, statistical method, and date of issue flows here too. Presenting something in a verifiable form is itself an implementation of honesty.

03The effect of excipients and naming other companies' products by brand

Here is a detail worth noting. Even when the active ingredient is identical, another company's product must be named by its brand name. It may not be grouped under a generic name.

The reason lies in the excipients. Compatibility is not decided by the active ingredient alone; it is also swayed by differences in pH adjusters, buffers, stabilizers, and solubilizers. Two products sharing an active ingredient may differ in buffering capacity and pH, and so behave differently when mixed. The moment they are lumped under a generic name, the reader is handed the false premise that "same ingredient means same result."

This treatment runs opposite to the rule, used in other materials, of citing competitors by generic name. Generic naming to avoid disparagement, brand naming to secure scientific rigor in compatibility—when the purpose differs, so does the practice. This calls for reasoning from intent rather than memorizing the rule by rote.

04Why "compatible" or "incompatible" must not be written

The heart of a compatibility table is to record results as physical and chemical facts only. Judgment words such as "may be combined," "compatible," or "incompatible" must not appear. What was observed is a change in appearance, a precipitate, a trend in content—facts. Ruling that "compatible" or "incompatible" is an act on a different plane.

The line drawn between fact and judgment

The instant you write "compatible," you have stepped out of observed fact into evaluation. Even if no change appeared under one set of conditions, a different concentration or a longer interval might bring one. A judgment word buries that limitation and gives the impression of an unconditional guarantee. Keep to a description of fact, and the reader retains room to re-examine under their own conditions.

This is scientific discipline itself. The observed event and the clinical judgment drawn from it are kept apart. The compatibility table carries the former; the latter is returned to the bedside. It is one continuous idea with the Guide's recurring demand to "state facts only and offer no evaluative commentary."

05Consistency with contraindications and precautions, and results that must not appear

The drugs listed in a compatibility table must be consistent with the important precautions and with the dosage and administration. A material does not stand alone; it sits inside the body of the authoritative source, the package insert. If the compatibility table alone puts out information at odds with the insert's precautions, the reader is stranded between two contradictory instructions.

Do not include test results with contraindicated combinations

Compatibility test results with drugs designated as contraindicated for combination must not be included, even when the result is "no change." However physically and chemically stable they proved, using those two drugs together is itself forbidden. Showing them to be stable at the compatibility level can become a false hint that they may be co-administered. Stability as a fact, and the permissibility of combining, belong to different layers.

For combination-caution drugs, note that fact

When a drug subject to combination caution is included in the table, the fact that it requires caution in combination must be written alongside. Confirmed compatibility stability does not erase the clinical caution. Placing the existence of that clinical caution next to the physicochemical fact keeps the reader from confusing the two layers.

06The duty to update

When the situation moves—at a change in prescribing practice, for instance—the compatibility table is updated as needed. When a new co-administration partner comes into clinical use, its result is added; when a formulation changes, the old result is reviewed. A compatibility table is not a notice posted once and left; it is a material that keeps living in step with the realities of prescribing.

This duty to update resonates with the closing demand running through the whole guideline: always record the date of issue or revision. Keep it clear which formulations the results rest on, and as of when. That makes later verification possible and stops stale information from walking off on its own.

→ Source page: Chapter 8: Compatibility Tables

Chapter 9: Conference Presentation Abstracts

A conference abstract or proceedings collection gathers the abstracts and records of presentations given at an academic congress or lecture meeting. At first glance it looks like a neutral record of a scientific meeting, yet the creation guide hedges this kind of material more tightly than almost any other chapter. The reason is plain. Much of what is presented at a congress has not yet settled into established medical evaluation. Findings confirmed through peer review sit on the same page as interim results shown in passing, and the reader tends to receive all of it as "facts endorsed by the congress." Once a pharmaceutical company puts its hand to such a collection, there is a real risk that unsettled information turns into a promotional tool.

01Its nature — material handed over on request

The starting point is that this material is provided in response to a request from a healthcare professional. It is not something a company distributes proactively. The abstract collection belongs to the same family as article reprints and abstract compilations, and all of them hold to a passive stance: you hand it over because the other party asked for it. Why insist so firmly on passivity?

If a company selects findings whose evaluation is unsettled, bundles them, and goes around handing them out, that act is in substance a message of "please look at this information." The moment it makes that approach, the material stops being something supplied on request and becomes promotional. The on-request premise is not mere procedure; it is a device for preserving the character of the information. That is exactly why the rules on web posting, discussed below, clearly forbid active solicitation by email and the like.

02Print run and period — restraint through quantity and time

The guide places concrete ceilings on quantity and duration. The print run is in principle no more than 5,000 copies, with a maximum of 10,000. The distribution period is in principle six months from the close of the congress, with a maximum of one year.

What matters is less the numbers than why numbers are used to bind at all. For material handed over on request, the quantity needed is naturally limited. Printing in bulk pushes beyond an on-request volume into a volume that presupposes distribution. The same logic governs time: keeping the material in circulation after the congress has gone stale and the evaluation has moved on leaves old interim results standing as if they were settled fact. The ceilings on quantity and time give the property of passivity a numerical backing.

03Selecting presentations — securing fairness

What to include and what to leave out is an editorial choice, and it is precisely in that choice that bias creeps in. The guide layers several conditions on the fairness of selection.

Select fairly from the whole congress

Presentations are chosen without bias from across the entire congress. Picking only presentations convenient to the company while dropping inconvenient ones turns the page from a record of the congress into the company's argument. The "cherry-picking" that Chapter 1 forbids reappears here in the form of presentation selection.

Cap the share of the company's own products

The number of presentations concerning the company's own products, and the share of the page they occupy, must not exceed half of the whole. The half line is unambiguous. If a majority of the collection is filled with the company's own products, it is no longer a record of the congress but a catalogue of those products. Measuring both count and page area closes the loophole of holding down the number of presentations while playing them up with large figures and tables.

Comparative clinical trials with fair allocation

If a comparative trial is included, choose one whose case allocation was carried out fairly. A trial with skewed allocation may itself yield skewed results. The scientific discipline that evidence quality is determined by study design is built into the selection criteria here as well.

Do not promote off-label use

Presentations that steer toward uses outside the approved indications or dosage must not be chosen. Congresses also feature pre-approval doses and off-label uses. Picking those up into the collection would mean the company had pushed off-label use. The principle the foreword sets out — never to exceed the approved scope by a single character — operates from the stage of presentation selection.

04Handling other companies' products — a structure against disparagement

The collection may include presentations on other companies' products. Their handling carries through Chapter 1's prohibition on slander and disparagement.

• Do not emphasize comparison with other companies' products in subheadings or in the titles of figures and tables.
• Do not center the selection on presentations unfavorable to other companies. This is the mirror image of fair selection: favoring one's own product and disfavoring a competitor are two faces of the same coin.

05Supervisor comments — keep to an overall review

Where a supervisor's comment accompanies the collection, it stays within the bounds of an overall review of the congress as a whole. No commentary may be added to individual presentations.

Why is individual commentary forbidden? If an expert annotates a particular presentation as "this finding is promising," authority is endorsed onto information whose evaluation is unsettled. Through the supervisor's words, the reader takes an unsettled conclusion as settled. The restriction to an overall review exists to prevent an expert's authority from being diverted into emphasizing individual data. This shares the logic by which Chapter 1 demands that animal and in vitro data not be tied directly to the clinic — a discipline of not mixing degrees of certainty that come from different sources.

06Cover and design — showing nature through the face

The cover carries the manufacturer's name, the congress name, the venue, and the dates. It further notes that the material is not an introduction to a specific drug but is provided on request, and that the electronic package insert should be consulted for each drug. This note is shown in gothic typeface at 10 points or larger, at a size that will not be overlooked.

That the cover specification reaches as far as appearance is no accident. The cover is the face of the material, the first place a reader reads its character. Fixing even the type size and typeface implements the foreword's "accurately, without misleading" as a physical matter of appearance. The thinking is the same as in Chapter 2, where the cover of a comprehensive product information summary must place the most important safety information in the reader's first field of view.

Avoid evoking the product

Designs, key visuals, and catchphrases that evoke a product are to be avoided, since they make the collection look like an advertisement for a specific product rather than a record of the congress. Color is held to two-color printing (black plus one color). Color is a means of emphasis, and limiting the number of colors narrows the very room to make something stand out visually. No advertisements are carried.

07Web posting — preserving passivity in the digital realm

Even as the medium shifts from paper to the web, the property of being handed over on request does not change. The foreword's assignment to "translate the manners of paper into the digital" takes concrete form here. Web posting is bound by the following.

• Keep it independent of the product page. Placing it within the flow of product promotion makes it part of advertising rather than material supplied on request.
• Limit viewing to the individual who made the request. A state where anyone can view it is no different from proactive provision.
• Do not allow viewing on a mere Yes/No click. Skipping a substantive confirmation that the viewer is a healthcare professional empties the limitation of meaning.
• Do not actively solicit by email or the like. The moment it solicits, it turns from passive to active.

08Why bind it this tightly — against the three design ideas

The rules for the abstract collection correspond one by one to the three pillars the foreword sets up. First, they block the "factual yet misleading." What was presented at the congress is fact, but the way of selecting and bundling can form a false picture — hence fair selection and the cap on the share of one's own products. Second, they implement balance. The constraints that one's own products not exceed half and that the selection not skew toward presentations unfavorable to competitors are balance made numerical. Third, they secure verifiability through structure. Stating the congress name, venue, and dates, noting that the package insert be consulted, and preserving sources create a state that can be checked afterward.

→ Source page: Chapter 9: Conference Presentation Abstracts

Chapter 10: Literature Reprints

Chapter 10 of Part III ("Other Materials") covers literature reprints. You take an article from a scholarly journal or a diagnosis-and-treatment guideline, and you hand it to a healthcare professional. At first glance this looks like the dullest, safest material of all: you are simply copying an existing paper and passing it along. Yet the Guide places no small number of fences here. Why would constraints be needed on a paper that someone else wrote and that has already cleared peer review? Answering that question is the key to reading this chapter.

01Why the Guide reaches a third party's paper

The foreword serves as the constitution of the whole Guide. Read closely, it carries the implication that what a company owes is not only the duty not to lie, but the duty not to mislead. Even when a fact is correct in itself, if the way it is presented forms a false picture in the recipient's mind, that can be a violation.

Reprints are where this duty not to mislead reappears in a changed form. The content of a paper is the work of a third party and has been peer-reviewed. The company does not alter a single word of it. And yet three choices remain in the company's hands: which paper to select, at what unit to extract it, and to whom and how to deliver it. The bias of selection and distribution can create a false impression without any tampering with the text. So the Guide places its fences not on the paper's content, but on the margin of choice the company still holds.

The foreword contains one more passage that cannot be overlooked: the Guide sets out basic matters and does not cover everything, and areas it does not regulate still fall under the Pharmaceutical and Medical Device Act, the Fair Advertising Standards, the information-provision guidelines, and the JPMA Code. This is a device to shut down the reading that "not in the manual = permitted." Whether to make a reprint, likewise, is not settled by mechanically checking the chapter's text; the Guide's stance is that you must scrutinize the content from the standpoint of the JPMA Code and the Chapter 1 basic considerations before deciding.

02"In response to a request" — material that is not pushed

A reprint is not a material to distribute actively. You hand it over only after a healthcare professional asks. This passivity is one of the three threads running through Part III — materials provided "on request" must not be pushed — applied to reprints.

Why must it be passive? Active mass distribution would turn a specific paper, and thus a specific viewpoint, into an advertising device imprinted on clinical practice. Even when the paper's content is neutral, if the distributor's intent is "I want this result seen widely," the act of distribution itself builds a biased information environment. Passivity is a structural fence to cut that circuit. It places the origin of the information flow on the healthcare professional's side, not the company's.

03Which papers may, and may not, become reprints

Not every paper can be made into a reprint. For literature touching on the efficacy of the company's own drug in particular, a line is drawn around what may be included.

What is excluded from efficacy literature

For literature concerning the efficacy of the company's own drug, reviews, overviews, articles, and contributions are not included as reprints. The reason for excluding these four lies in the discipline of evidence the foreword sets out.

Scientific evidence has a hierarchy. Meta-analyses and systematic reviews sit at the top, followed by randomized controlled trials, observational studies, and case reports, with expert opinion and narrative reviews at the bottom. The presence or absence of peer review is the watershed of quality. Reviews and overviews re-assemble multiple studies through the author's lens, and the author's interpretation enters. Articles and contributions are likewise processed discourse rather than primary data.

In efficacy — the domain most prone to exaggeration — making these into reprints would let a company present "an author's favorable interpretation" as though it were primary evidence. So the reprinting of efficacy literature is narrowed to original papers that interpose no interpretive layer. This is the reprint-version expression of the "scientific basis, fairness, objectivity" that Chapter 1 repeats.

The unit of extraction

Reprinting is done at an appropriate unit, such as the whole article. If you pull out only part of a paper and drop the statements of conclusion or limitation, the caveats the original carefully placed disappear. Extracting only a figure, or a single paragraph of the discussion, risks distorting the original's true intent. Taking the paper as the self-contained unit it is becomes the way, in the reprint setting, to uphold Chapter 1's principles of "do not distort the source data" and "do not present only favorable results."

04Web posting — the passivity that digitization easily breaks

The foreword notes that the media for materials have evolved from paper toward digital and the Web. And it carries the implication that how to translate paper-era practice into digital remains an assignment. Web posting of reprints is where that assignment surfaces most sharply.

For a paper reprint, "hand it over on request" holds naturally. But the moment you post it on the Web, it tends to become accessible to anyone, and the design principle of passivity collapses. So the Guide sets concrete conditions for preserving passivity even in digital form.

Conditions to preserve passivity

• Keep it independent from the product page. Built into a product's promotional flow, a reprint becomes advertising in effect. Separate the information's entrance from product promotion.
• Limit it to the individual requester. Make it viewable only by the person who asked. Open it to an unspecified crowd and the premise of "on request" collapses.
• Do not make it viewable by a mere Yes/No. A form where anyone enters by pressing one confirmation button is no different from outright publication. A mechanism to verify the authenticity of the request is needed.
• Do not actively solicit by email or the like. Sending "a reprint is available here" is active distribution dressed as passive. Such steering crosses the "do not push" line of Chapter 2.

05Three questions that govern a reprint

You do not need to memorize the chapter's text. When you make a reprint, asking yourself the following three will keep the spirit of the Guide largely intact.

1. Is this something put out because it was requested, or because you wanted to put it out? If the latter, suspect a disguise of passivity.
2. Do the selection and the extraction distort the original's true intent? For efficacy, is it narrowed to the original paper, and is it complete at the article unit?
3. If posted on the Web, is it designed to reach only the person who asked? Is it independent from the product flow, and free of steering?

→ Source page: Chapter 10: Literature Reprints

Chapter 11: Literature Abstract Collections

A literature abstract collection is a single resource that gathers summaries of several original research papers into one bound piece. Instead of handing over one reprint, the maker edits and binds the abstracts of multiple papers. Convenience comes at a price: because an act of editing sits in the middle, the maker's intent slips in more easily. It is no accident that this resource closes Part III. Within the family of materials provided on request — abstract collections, reprints, proceedings — the literature abstract collection is the one where the editor's hand reaches furthest, and so the guardrails around it are the heaviest.

01Standing — Why "on request" is the premise

A literature abstract collection is a resource provided in response to a healthcare professional's request. It is not something to hand out proactively. And the format itself must not give the impression that proactive distribution is the premise. The spirit of the foreword bears directly here. Just as the product information summary is a subordinate piece that "supplements" the package insert, the abstract collection is a passive tool that answers when a physician comes to seek information.

Why must it be passive? Because a collection of third-party papers looks, at first glance, like neutral academic information rather than a company's claim. Use that neutral guise to push a product, and you commit the violation the foreword fears most: "true, yet misleading." The papers may be genuine, but if the binding is advertising, the whole is advertising.

02Quality of material — Peer-reviewed originals only

A collection may be built only from abstracts of original papers that have passed rigorous peer review. Reviews, narrative reviews, articles, and contributed pieces are excluded. This drops the discipline of the evidence hierarchy straight into resource design.

Peer review is the watershed that separates the quality of scientific claims. An original paper that has been peer reviewed has had its methods and results pass third-party scrutiny. A review, by contrast, is the author's argued selection from existing studies; the author's interpretation and choices are necessarily baked in. Bind reviews and you get "a bundle of interpretations"; bind originals and you get "a bundle of primary data." What a collection demands is the latter.

03Selection criteria — Securing objectivity by stating it

Which papers to include must be decided by objective criteria, and those criteria must be stated in the resource — for example, by recording that a neutral editorial committee selects papers against clear, explicit standards.

This is the vital point of the collection. Paper selection is the quietest and most effective stage at which to manipulate impression. Gather only the convenient papers and drop those with unfavorable results, and every individual summary stays accurate while the whole forms a slanted picture. The "ban on deliberate omission" common to Part III's lists and comparisons takes, in the collection, the concrete form of "stating the selection criteria."

Why writing the criteria down acts as a guardrail

Once selection criteria are recorded in the document, those criteria become verifiable from outside. To the question "under this criterion, shouldn't that unfavorable paper also be included?", the maker now has to answer by the criterion. Forcing the standard into writing itself restrains arbitrary cherry-picking. This applies one of the foreword's three pillars — "securing verifiability by structure." By making the procedure disclosed, the fairness of the result can be inspected after the fact.

04The ban on processing — Faithfully reflecting the original's intent

Each summary must faithfully reflect the true intent of the original paper. No biased processing. No additions of things the original does not state. No claims in the summary that go beyond the original.

Summarizing is, by nature, an act of cutting. In cutting, a judgment about what to keep and what to discard always enters. If that judgment leans systematically toward what favors the product, the summary stops representing the original and becomes a substitution of the company's claim. The same discipline as Chapter 1's "quote guidelines verbatim, reflect the intent faithfully" is imposed here on original papers.

The condition "no additions beyond the original" weighs especially heavily. Add to the summary an implication or clinical value the original never showed, and that is a fresh claim built on the original as a stepping stone — groundless exaggeration. The summarizer's job is translation, not invention.

05Limits of content — Three lines never to cross

The content of a collection must not cross the following three lines. Each is the collection's form of a prohibition that runs through the whole guide.

• It must not lead to recommending off-label use. Even if an original paper covers uses or indications outside the approval, it must not be bound in a context that recommends them. The approved content is the master text, and the collection cannot exceed it by a single character.
• It must not lead to disparagement. Do not center the collection on papers unfavorable to competitors, or arrange comparator results so as to denigrate them.
• It must not lead to recommending uses that conflict with the precautions and related information. Do not, through summaries, suggest a manner of use that contradicts the warnings, contraindications, or precautions in the package insert.

Color as a hard-to-see manipulation

The coloring of abstracts must follow the original or be more restrained than the original. Take figures the original printed in black and white, and color only the product-favorable data in the collection, and you steer the reader's gaze without altering a single character of text. This shares the thinking of Chapter 1's "no emphasis by color or bold." Emphasis is achieved not only by text but by visual effect. By specifying even the tone of color, the guide blocks misdirection through appearance.

06Cover and bibliography — Declaring passivity and verifiability

The cover must state, in gothic type of at least 10 points, that the package insert should be consulted and that the resource is provided on request. The type size is fixed because these are function, not decoration. The line "on request" is a declaration that this resource is a passive tool; the line "consult the package insert" is the caveat that a summary collection is no substitute for the master text.

The bibliographic details of each paper must be recorded accurately. The selection criteria for papers and the scope of the company's involvement must also be stated, along with the company name. If the bibliography is accurate, readers can go to the originals and judge for themselves whether the summaries are sound. If the scope of involvement is disclosed, readers can read while weighing the conflict of interest. Both are requirements for creating a state that can be verified after the fact.

→ Source page: Chapter 11: Literature Abstract Collections